Abstract
Plin is a non-G-CSF small molecule, with anti-cancer activity, and prevents CIN as single agent and in combination with Peg. In the phase (Ph) III trial PROTECTIVE-2 (NCT03294577), the Plin+Peg combination had superior CIN preventive efficacy versus (vs) Peg alone for Grade 4 neutropenia (Gr4N) (86% vs 68% for Peg alone, p<0.0015), for days of severe neutropenia (DSN, p=0.03), absolute neutrophil count (ANC) nadir (p=0.0002) (Blayney ASCO 2021). We evaluated the impact of the observed reduction in Gr4N from 86% with Peg alone to 68% with Plin+Peg on CIN outcomes using a MA.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
